- Initial Statement of Beneficial Ownership (3)
April 09 2010 - 4:25PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Expires:
February 28, 2011
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Davies Angela M.
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/1/2010
|
3. Issuer Name
and
Ticker or Trading Symbol
OSI PHARMACEUTICALS INC [OSIP]
|
(Last)
(First)
(Middle)
C/O OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
Sr. VP and CMO, Oncology /
|
(Street)
MELVILLE, NY 11747
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Common Stock
|
5718
(1)
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (Right to Buy)
|
3/3/2009
(2)
|
3/2/2015
|
Common Stock
|
18900
(4)
|
$38.13
|
D
|
|
Stock Option (Right to Buy)
|
12/16/2009
(2)
|
12/15/2015
|
Common Stock
|
2580
(4)
|
$33.62
|
D
|
|
Stock Option (Right to Buy)
|
12/15/2010
(3)
|
12/14/2019
|
Common Stock
|
9000
(4)
|
$35.40
|
D
|
|
Explanation of Responses:
|
(
1)
|
Consists of (i) 743 shares of Common Stock and (ii) 4,975 Restricted Stock Units, which vest over a period of 4 years from their respective dates of grant. Dr. Davies will receive one share of OSI Common Stock upon the vesting of each Restricted Stock Unit.
|
(
2)
|
25% of the option became exerciseable one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years.
|
(
3)
|
25% of the option will become exerciseable one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years.
|
(
4)
|
Includes only options with the same termination date.
|
Remarks:
Exhibit List:
Exhibit 24--Power of Attorney
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Davies Angela M.
C/O OSI PHARMACEUTICALS, INC.
41 PINELAWN ROAD
MELVILLE, NY 11747
|
|
|
Sr. VP and CMO, Oncology
|
|
Signatures
|
/s/ Pierre Legault, attorney-in-fact for Dr. Davies
|
|
4/9/2010
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
More News Articles